Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users

被引:42
|
作者
Reneman, Liesbeth
Schilt, T.
de Win, Maartje M.
Booij, Jan
Schmand, Ben
van den Brink, Wim
Bakker, Onno
机构
[1] Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci, Dept Neurol, NL-1105 BC Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci, Dept Radiol, NL-1105 BC Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci, Dept Nucl Med, NL-1105 BC Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci, Dept Psychiat, NL-1105 BC Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci, Amsterdam Inst Addict Res, NL-1105 BC Amsterdam, Netherlands
[6] Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci, Dept Expt Endocrinol, NL-1105 BC Amsterdam, Netherlands
关键词
MDMA; 5-HT neurotoxicity; cognition; long-term effects; 5-HTTLPR;
D O I
10.1177/0269881106063266
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although 3,4-methytenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the tong-term consequences of MDMA-induced 5-HT neurotoxic Lesions on functions in which 5-HT is involved, such as cognitive function. Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning. The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of Longterm abstention from MDMA, in subjects genotyped for 5-HTTLPR. A second aim of the study was to determine whether these effects differ for females and mates. Fifteen moderate MDMA users (< 55 Lifetime tablets), 22 heavy MDMA+ users (> 55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests. DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods. A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59). Heavy and ex-MDMA+ users performed significantly poorer on memory tasks than controls. In contrast, no evidence of memory impairment was observed in moderate MDMA users. No significant effect of 5-HTTLPR or gender was observed. While the use of MDMA in quantities that may be considered 'moderate' is not associated with impaired memory functioning, heavy use of MDMA use may lead to tong lasting memory impairments. No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.
引用
收藏
页码:389 / 399
页数:11
相关论文
共 50 条
  • [31] Working memory deficits in current and previous users of MDMA ('ecstasy')
    Wareing, M
    Fisk, JE
    Murphy, PN
    BRITISH JOURNAL OF PSYCHOLOGY, 2000, 91 : 181 - 188
  • [32] Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter
    K. P. C. Kuypers
    R. de la Torre
    M. Farre
    L. Xicota
    E. B. de Sousa Fernandes Perna
    E. L. Theunissen
    J. G. Ramaekers
    Scientific Reports, 8
  • [33] Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
    E Smeraldi
    R Zanardi
    F Benedetti
    D Di Bella
    J Perez
    M Catalano
    Molecular Psychiatry, 1998, 3 : 508 - 511
  • [34] Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter
    Kuypers, K. P. C.
    de la Torre, R.
    Farre, M.
    Xicota, L.
    Perna, E. B. de Sousa Fernandes
    Theunissen, E. L.
    Ramaekers, J. G.
    SCIENTIFIC REPORTS, 2018, 8
  • [35] Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use
    Gouzoulis-Mayfrank, E
    Fischermann, T
    Rezk, M
    Thimm, B
    Hensen, G
    Daumann, J
    DRUG AND ALCOHOL DEPENDENCE, 2005, 78 (03) : 317 - 323
  • [36] Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene
    Perna, G
    Favaron, E
    Di Bella, D
    Bussi, R
    Bellodi, L
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 (12) : 2230 - 2235
  • [37] Serotonin transporter gene promoter polymorphism, education, depression and relations with partner
    Kurrikoff, T.
    Maestu, J.
    Nordquist, N.
    Oreland, L.
    Harro, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S236 - S236
  • [38] Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
    Smeraldi, E
    Zanardi, R
    Benedetti, F
    Di Bella, D
    Perez, J
    Catalano, M
    MOLECULAR PSYCHIATRY, 1998, 3 (06) : 508 - 511
  • [39] Antipanic Efficacy of Paroxetine and Polymorphism within the Promoter of the Serotonin Transporter Gene
    Giampaolo Perna
    Elisa Favaron
    Daniela Di Bella
    Riccardo Bussi
    Laura Bellodi
    Neuropsychopharmacology, 2005, 30 : 2230 - 2235
  • [40] In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") and Hallucinogen Users
    Erritzoe, David
    Frokjaer, Vibe G.
    Holst, Klaus K.
    Christoffersen, Maria
    Johansen, Sys S.
    Svarer, Claus
    Madsen, Jacob
    Rasmussen, Peter M.
    Ramsoy, Thomas
    Jernigan, Terry L.
    Knudsen, Gitte M.
    ARCHIVES OF GENERAL PSYCHIATRY, 2011, 68 (06) : 562 - 576